CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

BACKGROUND: Patients with severe, uncontrolled asthma, particularly those with a non-eosinophilic phenotype, have a great unmet need for new treatments that act on a broad range of inflammatory pathways in the airway. Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Emson, Claire, Diver, Sarah, Chachi, Latifa, Megally, Ayman, Small, Cherrie, Downie, John, Parnes, Jane R., Bowen, Karin, Colice, Gene, Brightling, Chris E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550845/
https://www.ncbi.nlm.nih.gov/pubmed/33050900
http://dx.doi.org/10.1186/s12931-020-01513-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550845/
https://www.ncbi.nlm.nih.gov/pubmed/33050900
http://dx.doi.org/10.1186/s12931-020-01513-x

Ejemplares similares